Clinical Trials Recruiting near Detroit, MI

948 clinical trials have a recruiting site within 25 miles of Detroit, Michigan, according to ClinicalTrials.gov data processed October 15, 2026. The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Recruiting now

Studies enrolling near Detroit

Showing 30 studies, nearest first.

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
- Observational
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
36 sites within 25 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
- Observational
- Ages 40 to 75 years
- Sex: All
- Accepts healthy volunteers
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
34 sites within 25 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
34 sites within 25 mi
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
28 sites within 25 mi
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
NCT04239573
- Observational
- Ages 50 to 75 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
25 sites within 25 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
- Phase 3
- Ages 18 to 60 years
- Sex: Female
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
24 sites within 25 mi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
23 sites within 25 mi
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
22 sites within 25 mi
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04205968
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
22 sites within 25 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
22 sites within 25 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
- Phase 3
- Ages 50 to 70 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
22 sites within 25 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
21 sites within 25 mi
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
NCT05058651
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
20 sites within 25 mi
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
19 sites within 25 mi
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
19 sites within 25 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
19 sites within 25 mi
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
18 sites within 25 mi
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
18 sites within 25 mi
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
17 sites within 25 mi
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
- Interventional
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
- Phase 3
- Ages Any age
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
15 sites within 25 mi
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410
- Phase 3
- Ages 5 to 60 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
15 sites within 25 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04181060
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
14 sites within 25 mi
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
NCT04871542
- Observational
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
14 sites within 25 mi
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243
- Phase 3
- Ages 18 years and older
- Sex: Male
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
14 sites within 25 mi

By condition

Clinical trials in Detroit by condition

Source: ClinicalTrials.gov, data processed October 15, 2026. Recruiting US sites filtered by distance and site status; summaries shortened.